However, the administration of BMS-477118, at doses of either 5 mg/kg or 10 mg/kg, to rats with chronic UC resulted in a significant reduction in NFκB activity compared to the untreated chronic colitis group (Figure 5D). This evidence concerns the gene NFKB1 and Chronic colitis.